CASE REPORT
Year : 2020 | Volume
: 12 | Issue : 4 | Page : 188--190
Clinical experience with oral tofacitinib in a patient with alopecia areata universalis and rheumatoid arthritis
Daniele Tiemi Abe, Letícia Mari Tashima, Flavia Machado Alves Basilio, Fabiane Mulinari-Brenner
Department of Dermatology, Federal University of Paraná, Curitiba, Paraná, Brazil
Correspondence Address:
Dr. Daniele Tiemi Abe
Rua General Carneiro, 181 - Alto da Gloria, Curitiba, Parana
Brazil
Alopecia areata (AA) is a chronic and autoimmune disease frequently characterized by a challenge management between dermatologists. At present, JAK-inhibitors have demonstrated encouraging results in AA treatment. Therefore, this study reports a case of alopecia universalis in a patient with rheumatoid arthritis (RA), whose methotrexate therapy shown unsatisfactory response in RA control. After the introduction of 10 mg (oral route) per day of tofacitinib, a JAK-inhibitor, an improvement of almost 50% in severity alopecia tool score occurred with maintained response even after 3 months of medication suspension. From this time, we corroborate the effectiveness of JAK-inhibitors presented in the scientific literature. In addition, we inquiry the real impact of methotrexate on JAK-start signaling inhibition in AA pathophysiology.
How to cite this article:
Abe DT, Tashima LM, Basilio FM, Mulinari-Brenner F. Clinical experience with oral tofacitinib in a patient with alopecia areata universalis and rheumatoid arthritis.Int J Trichol 2020;12:188-190
|
How to cite this URL:
Abe DT, Tashima LM, Basilio FM, Mulinari-Brenner F. Clinical experience with oral tofacitinib in a patient with alopecia areata universalis and rheumatoid arthritis. Int J Trichol [serial online] 2020 [cited 2023 Jan 30 ];12:188-190
Available from: https://www.ijtrichology.com/article.asp?issn=0974-7753;year=2020;volume=12;issue=4;spage=188;epage=190;aulast=Abe;type=0 |
|
|
|
